GE HealthCare has welcomed a new addition to its line of handheld ultrasound devices: the Vscan Air SL, featuring a dual-probe design for quickly assessing heart and blood vessel issues at the point of care.

GE HealthCare欢迎在其手持式超声设备系列中增加新产品：Vscan Air SL，具有双探头设计，可在护理点快速评估心脏和血管问题。

The company hopes that clinicians will carry around the pocket-sized, wireless scanner and use it as needed, instead of relying on wheeled ultrasound carts, with a special focus on emergency situations that may require a fast diagnosis.

该公司希望临床医生携带口袋大小的无线扫描仪并根据需要使用，而不是依靠车轮超声车，特别关注可能需要快速诊断的紧急情况。

The cardiovascular disease-focused SL, with its sector-phased array transducer, joins the Vscan Air CL—introduced in 2021 and equipped with a curved array designed for easier abdominal and obstetric imaging—as well as the Vscan Extend, with its connected handheld screen. Both the SL and CL also employ a linear array on the device’s opposite side to help take pictures of the lungs, skeletal system and more..

以心血管疾病为中心的SL与其扇形相控阵换能器一起加入2021年推出的Vscan Air CL，并配备弯曲阵列，设计用于更容易的腹部和产科成像以及Vscan扩展，并连接手持式屏幕。SL和CL在设备的另一侧也采用线性阵列来帮助拍摄肺部，骨骼系统等。。

The Vscan line first made its debut in 2010; according to GE HealthCare, more than 50,000 Vscan systems have since been used to help care for about 100 million patients worldwide.

Vscan系列于2010年首次亮相；根据GE HealthCare的说法，此后已使用50000多个Vscan系统来帮助护理全球约1亿患者。

The Vscan Air SL is already commercially available in Europe, Asia, Australia and New Zealand. The company said the device has now been cleared by the FDA, and it expects to begin U.S. shipments this quarter.

Vscan Air SL已在欧洲，亚洲，澳大利亚和新西兰上市。该公司表示，该设备现已被FDA批准，预计本季度将开始美国发货。

Sharing the stage with the Vscan Air SL, with announcements timed for the annual meeting of the European Society of Cardiology in Amsterdam, GE HealthCare also launched CardioVisio for Atrial Fibrillation, a digital clinical decision support tool.

与Vscan Air SL分享舞台，并在阿姆斯特丹举行的欧洲心脏病学会年会上发布公告，GE HealthCare还推出了数字临床决策支持工具CardioVisio for心房颤动。

The program culls data from multiple sources and afib guidelines to help model disease progression and make therapy recommendations. With afib being the most common arrhythmia, GE HealthCare estimates that nearly 16 million people could receive a diagnosis in the U.S. by 2050, as well as nearly 18 million in Europe by 2060.

该程序从多个来源和afib指南中剔除数据，以帮助模拟疾病进展并提出治疗建议。由于afib是最常见的心律失常，GE HealthCare估计到2050年美国将有近1600万人接受诊断，到2060年欧洲将有近1800万人接受诊断。

At the same time, afib is often misdiagnosed, with up to 30% of cases missed in clinical practice, the company said..

同时，afib经常被误诊，临床实践中漏诊率高达30%。。